Structural basis for HIV-1 Gag interactions with cellular and viral constituents

HIV-1 Gag 与细胞和病毒成分相互作用的结构基础

基本信息

  • 批准号:
    9979755
  • 负责人:
  • 金额:
    $ 45.65万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2010
  • 资助国家:
    美国
  • 起止时间:
    2010-05-15 至 2023-08-31
  • 项目状态:
    已结题

项目摘要

During the late phase of HIV-1 infection, the Gag polyproteins are transported to the plasma membrane (PM) for assembly. Gag targeting and assembly on the PM is dependent on specific interactions between its matrix (MA) domain and phosphatidylinositol 4,5-bisphosphate (PI(4,5)P2), a signaling lipid localized on the inner leaflet of the PM. Concurrent or subsequent to Gag assembly, the envelope (Env) protein is recruited to the PM for incorporation into virus particles, a process that is dependent on Gag assembly. Several lines of evidence suggest that incorporation of Env is mediated by interactions between the MA domain of Gag and the cytoplasmic tail of gp41 (gp41CT), a mechanism that remains to be elucidated. For over a decade, we have pioneered approaches to investigate at the molecular level how retroviral (HIV-1, HIV-2, MLV, and ASV) MA domains of Gag interact with lipids (e.g., PI(4,5)P2) and membranes, a key requirement for understanding Gag assembly and ultimately Env incorporation. A major barrier to characterizing gp41CT–MA interaction has been the unavailability of a recombinant gp41CT protein and the inability to reconstitute the proper conditions for the interaction to occur. During this funding period we have recorded a breakthrough by determining the three- dimensional structure of HIV-1 gp41CT and characterized its interaction with membrane. This achievement, an elusive task for over two decades, filled a major gap by providing the structure of the last segment of HIV-1 proteome. In this renewal, we set our sights on elucidating the molecular mechanism by which Gag mediates the recruitment of HIV-1 Env into assembly sites. We will test the hypothesis that trimerization of the MA domain plays an important role in gp41CT interaction and therefore Env recruitment into particles. We will employ a battery of structural biology, biophysical, and biochemical tools to generate a macromolecular picture of how the MA domain of Gag binds to membrane and how it interacts with gp41CT. Our specific aims are: (i) Engineer HIV-1 MA trimer and hexamer and characterize their binding to membranes, (ii) characterize the interactions between HIV-1 MA and gp41CT, and (iii) determine the structure of MA–gp41(TM-CT)–membrane complex by single-particle cryo-EM. This proposal rests on a solid premise of: (1) 25 years of functional data that is waiting for a molecular interpretation to provide sharper insights into Gag assembly on the PM and mechanisms of Env incorporation, (2) highly technical skill sets for working with proteins, membranes, structural and biophysical tools, (3) strong preliminary data, and (4) an outstanding collaborative team with 20-30 years of experience in cryo-EM, x-ray crystallography, and mass spectrometry. Therefore, the proposed structural studies will provide a detailed understanding of HIV-1 Gag assembly on the PM and Gag–mediated Env incorporation. We hope that the outcome of this proposal will help in the development of new antiviral therapeutic agents that inhibit assembly, Env incorporation and ultimately virus production.
在HIV-1感染的后期,Gag多蛋白被转运到质膜(PM)进行感染

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

Jamil Subhi Saad其他文献

Jamil Subhi Saad的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('Jamil Subhi Saad', 18)}}的其他基金

Structural basis for cellular secretion and uptake of HIV-1 Tat
HIV-1 Tat 细胞分泌和摄取的结构基础
  • 批准号:
    9926634
  • 财政年份:
    2020
  • 资助金额:
    $ 45.65万
  • 项目类别:
Structural basis for HIV-1 Gag interactions with cellular constituents
HIV-1 Gag 与细胞成分相互作用的结构基础
  • 批准号:
    8457022
  • 财政年份:
    2010
  • 资助金额:
    $ 45.65万
  • 项目类别:
Structural basis for HIV-1 Gag interactions with cellular and viral constituents
HIV-1 Gag 与细胞和病毒成分相互作用的结构基础
  • 批准号:
    10226955
  • 财政年份:
    2010
  • 资助金额:
    $ 45.65万
  • 项目类别:
Structural Basis for HIV-1 Gag Interactions with Cellular Constituents
HIV-1 Gag 与细胞成分相互作用的结构基础
  • 批准号:
    9147626
  • 财政年份:
    2010
  • 资助金额:
    $ 45.65万
  • 项目类别:
Structural basis for HIV-1 Gag interactions with cellular constituents
HIV-1 Gag 与细胞成分相互作用的结构基础
  • 批准号:
    8638883
  • 财政年份:
    2010
  • 资助金额:
    $ 45.65万
  • 项目类别:
Structural Basis for HIV-1 Gag Interactions with Cellular Constituents
HIV-1 Gag 与细胞成分相互作用的结构基础
  • 批准号:
    9340233
  • 财政年份:
    2010
  • 资助金额:
    $ 45.65万
  • 项目类别:
Structural basis for HIV-1 Gag interactions with cellular constituents
HIV-1 Gag 与细胞成分相互作用的结构基础
  • 批准号:
    8073053
  • 财政年份:
    2010
  • 资助金额:
    $ 45.65万
  • 项目类别:
Structural basis for HIV-1 Gag interactions with cellular constituents
HIV-1 Gag 与细胞成分相互作用的结构基础
  • 批准号:
    8011917
  • 财政年份:
    2010
  • 资助金额:
    $ 45.65万
  • 项目类别:
Structural Basis for HIV-1 Gag Interactions with Cellular Constituents
HIV-1 Gag 与细胞成分相互作用的结构基础
  • 批准号:
    9304625
  • 财政年份:
    2010
  • 资助金额:
    $ 45.65万
  • 项目类别:
Structural basis for HIV-1 Gag interactions with cellular and viral constituents
HIV-1 Gag 与细胞和病毒成分相互作用的结构基础
  • 批准号:
    10462579
  • 财政年份:
    2010
  • 资助金额:
    $ 45.65万
  • 项目类别:

相似海外基金

Development of a new generation of antiviral agents that are effective against drug-resistant viruses and prevent serious illness and sequelae.
开发新一代抗病毒药物,可有效对抗耐药病毒并预防严重疾病和后遗症。
  • 批准号:
    23K18186
  • 财政年份:
    2023
  • 资助金额:
    $ 45.65万
  • 项目类别:
    Grant-in-Aid for Challenging Research (Exploratory)
A versatile structure-based therapeutic platform for development of VHH-based antitoxin and antiviral agents
一个多功能的基于结构的治疗平台,用于开发基于 VHH 的抗毒素和抗病毒药物
  • 批准号:
    10560883
  • 财政年份:
    2023
  • 资助金额:
    $ 45.65万
  • 项目类别:
Genetically encoded bicyclic peptide libraries for the discoveryof novel antiviral agents
用于发现新型抗病毒药物的基因编码双环肽库
  • 批准号:
    10730692
  • 财政年份:
    2021
  • 资助金额:
    $ 45.65万
  • 项目类别:
Design and synthesis of nucleosides to develop antiviral agents and oligonucleotide therapeutics
设计和合成核苷以开发抗病毒药物和寡核苷酸疗法
  • 批准号:
    21K06459
  • 财政年份:
    2021
  • 资助金额:
    $ 45.65万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
Genetically encoded bicyclic peptide libraries for the discoveryof novel antiviral agents
用于发现新型抗病毒药物的基因编码双环肽库
  • 批准号:
    10189880
  • 财政年份:
    2021
  • 资助金额:
    $ 45.65万
  • 项目类别:
Computer-aided identification and synthesis of novel broad-spectrum antiviral agents
新型广谱抗病毒药物的计算机辅助鉴定和合成
  • 批准号:
    2404261
  • 财政年份:
    2020
  • 资助金额:
    $ 45.65万
  • 项目类别:
    Studentship
Develop broad-spectrum antiviral agents against COVID-19 based on innate immune response to SARS-CoV-2 infection
基于对 SARS-CoV-2 感染的先天免疫反应,开发针对 COVID-19 的广谱抗病毒药物
  • 批准号:
    10222540
  • 财政年份:
    2020
  • 资助金额:
    $ 45.65万
  • 项目类别:
Develop broad-spectrum antiviral agents against COVID-19 based on innate immune response to SARS-CoV-2 infection
基于对 SARS-CoV-2 感染的先天免疫反应,开发针对 COVID-19 的广谱抗病毒药物
  • 批准号:
    10669717
  • 财政年份:
    2020
  • 资助金额:
    $ 45.65万
  • 项目类别:
Association between sedentary lifestyle and liver cancer development in hepatitis C patients treated with direct-acting antiviral agents
接受直接抗病毒药物治疗的丙型肝炎患者久坐的生活方式与肝癌发展之间的关系
  • 批准号:
    20K10713
  • 财政年份:
    2020
  • 资助金额:
    $ 45.65万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
Develop broad-spectrum antiviral agents against COVID-19 based on innate immune response to SARS-CoV-2 infection
基于对 SARS-CoV-2 感染的先天免疫反应,开发针对 COVID-19 的广谱抗病毒药物
  • 批准号:
    10174522
  • 财政年份:
    2020
  • 资助金额:
    $ 45.65万
  • 项目类别:
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了